Fannin Innovation Studio Accepted Into NIDA's Medications Discovery Program
Fannin Innovation Studio, an early-stage biomedical development and commercialization company, announces that the company will be partnering with the National Institute of Drug Abuse (NIDA), a federal scientific research institute under the National Institutes of Health (NIH), to test 11h, Fannin's lead clinical candidate for its substance use disorder (SUD) program.
HOUSTON, Oct. 3, 2022 /PRNewswire-PRWeb/ -- Fannin Innovation Studio, an early-stage biomedical development and commercialization company, announces that the company will be partnering with the National Institute of Drug Abuse (NIDA), a federal scientific research institute under the National Institutes of Health (NIH), to test 11h, Fannin's lead clinical candidate for its substance use disorder (SUD) program.
The research will be conducted by NIDA's Division of Therapeutics and Medical Consequences (DTMC) under the Addiction Treatment Discovery Program (ATDP). Experts at the DTMC will evaluate 11h in a series of preclinical pharmacologic and toxicologic protocols to determine its effectiveness and safety in the treatment of SUDs. Fannin will provide 11h, and will work with the DTMC scientists to select the appropriate protocols and dosing parameters for these tests. Fannin will retain all intellectual property, proprietary and commercialization rights to these compounds.
"We appreciate NIDA's vote of confidence in accepting 11h into the ATDP", said Atul Varadhachary, MD, PhD, and Managing Partner at Fannin. "NIDA's active engagement will accelerate our program and provide an additional independent assessment of 11h as we advance it towards clinical development."
11h is the lead SUD clinical candidate being developed by Fannin's Goldenrod program. 11h is part of a broad set of compounds developed by Professor Corey Hopkins, at the Department of Pharmaceutical Sciences (College of Pharmacy) in the University of Nebraska Medical Center and licensed to Fannin in June 2020, for further scientific and commercial development. 11h, is a selective dual inhibitor of PDE4B and CB1R, both validated pathways for addressing OUD. 11h, which was designed to reduce the major toxicities associated with existing PDE4 and CB1R inhibitors, is orally bioavailable, CNS penetrant, has demonstrated promising activity in animal models of OUD, and appears to be well tolerated.
"11h has the potential to significantly supplement current standard of care in a number of substance use disorders, some of which currently lack any approved pharmaceutical treatment options", said Fannin's Managing Director, Dev Chatterjee, MD, PhD. "The mechanism of action of the drug applies across SUDs and, if successful, the drug can help millions of sufferers with a broad range of SUDs."
About Fannin Innovation Studio
Fannin is Houston's most active biomedical development group focused on developing early-stage pharmaceutical and medical device assets, both those in-licensed from academic institutions and those developed internally. Fannin has created a broad pipeline of programs through the expertise of its experienced research and development team and its extensive network of scientists, clinicians and industry leaders. Fannin advances its pipeline both internally and through Fannin Founded Entities with a combination of investor and grant funding.
For more information, visit http://www.fannininnovation.com.
Media Contact
Serena Miggins, Fannin Innovation Studio, 1 7139665844, [email protected]
SOURCE Fannin Innovation Studio
Share this article